NASDAQ : DCPH

Deciphera Pharmaceuticals, Inc.

$25.59 USD

$0.02 (0.08%)

Volume
1.57M
Average Volume
1.92M
Market Capitalization
$2.21B
P/E Ratio
-11.17
Dividend Yield
0.00%
Price Target
$25.60
Year High
$25.61
Year Low
$9.90
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.80
Company Overview

NASDAQ

Steven L. Hoerter

Drug Manufacturers - Specialty & Generic

Healthcare

DCPH

355

US

USD

https://www.deciphera.com

781 209 6400

24344T101

0001654151

Liquidity Metrics

0.07

3.80

3.59

0.83

0.00

Sales & Valuation

$163.36M

13.55

6.20

-15.01

-1.73

Profitability

-$2.29

-$194.94M

-119.34%

-119.07%

-56.29%

-41.16%

P/E Metrics

-11.17

-3.93

-3.93

Analyst Price Target & Rating

$25.60

$30.00

$25.00

N/A

0/5

26 Analysts

-0.04%

Financial Health Scores

7.38

3/9

$266.51M

$420.93M

$104.88M

-$198.42M

Key Metrics (TTM)

$2.16B

13.19

-10.32

3.80

-56.29%

-55.99%

-8.96%

-6.66%

-444 days

Company Executives
Name Title
Daniel C. Martin Senior Vice President & Chief Commercial Officer
Steven L. Hoerter President, Chief Executive Officer & Director
Thomas Patrick Kelly Executive Vice President, Chief Financial Officer & Treasurer
Dashyant Dhanak Executive Vice President & Chief Scientific Officer
Kevin Brodbeck Senior Vice President & Chief Technical Officer
Madhumita Bogdan Senior Principal Investigator of Biological Sciences
Jeffrey Held Senior Vice President & General Counsel
Jama Pitman Senior Vice President & Chief Development Officer
Kelley Dealhoy Senior Vice President & Chief Business Officer
Lisa Amaya Price Senior Vice President & Chief Human Resources Officer
Margarida Duarte Senior Vice President & Head of International
Rodrigo Ruiz Soto Senior Vice President of Clinical Development
Jennifer Larson Senior Vice President of Finance & Investor Relations
Jennifer Robinson Vice President of Investor Relations
Matthew L. Sherman Executive Vice President & Chief Medical Officer
Poll Results

No votes yet today — be the first to share your view!

About Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally. The company's flagship product, QINLOCK, is employed in the treatment of gastrointestinal stromal tumors (GIST) and is additionally undergoing a Phase 3 clinical trial (INTRIGUE study) for second-line GIST. Deciphera's pipeline also includes vimseltinib, a potent, orally available, and highly selective switch-control kinase inhibitor targeting colony stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT). Fur ... thermore, they are advancing DCC-3116, currently in preclinical development, which targets RAS/RAF mutant cancers. Established in 2003, Deciphera Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Frequently Asked Questions

What is the current Deciphera Pharmaceuticals, Inc. (DCPH) stock price?

Deciphera Pharmaceuticals, Inc.(NASDAQ:DCPH) stock price is $25.59 in the last trading session. During the trading session, DCPH stock reached the peak price of $25.61 while $9.9 was the lowest point it dropped to. The percentage change in DCPH stock occurred in the recent session was 0.08% while the dollar amount for the price change in DCPH stock was $0.02.

DCPH's industry and sector of operation?

The NASDAQ listed DCPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of DCPH?

Daniel C. Martin | Senior Vice President & Chief Commercial Officer
Steven L. Hoerter | President, Chief Executive Officer & Director
Thomas Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer
Dashyant Dhanak | Executive Vice President & Chief Scientific Officer
Kevin Brodbeck | Senior Vice President & Chief Technical Officer

How many employees does DCPH have?

Number of DCPH employees currently stands at 355. DCPH operates from 200 Smith Street, Waltham, MA 02451, US.

Link for DCPH official website?

Official Website of DCPH is: https://www.deciphera.com

How do I contact DCPH?

DCPH could be contacted at phone #781 209 6400 and can also be accessed through its website. DCPH operates from 200 Smith Street, Waltham, MA 02451, US.

How many shares of DCPH are traded daily?

The average number of DCPH shares traded daily for last 3 months was 1.92M.

What is the market cap of DCPH currently?

The market value of DCPH currently stands at $2.21B with its latest stock price at $25.59